Evidence map›Paper›PMID 35125692›Full record

ArticleIndian journal of clinical biochemistry : IJCB2022

Development of Flow Injection Analysis Method for the Second-Tier Estimation of Succinylacetone in Dried Blood Spot of Newborn Screening.

Bijo Varughese, Dnyanoba Madrewar, Sunil Kumar Polipalli, Seema Kapoor

Open access · greenAbstract read
In one paragraph

Article in Indian journal of clinical biochemistry : IJCB, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Bijo VarugheseDepartment of Paediatrics, Paediatrics Research and Genetic Lab, Maulana Azad Medical College (University of Delhi) and Associated Lok Nayak Hospital, New Delhi, 110002 India.
Dnyanoba MadrewarPerkin Elmer Pvt. Ltd, Mumbai, Maharashtra India.
Sunil Kumar PolipalliDepartment of Paediatrics, Paediatrics Research and Genetic Lab, Maulana Azad Medical College (University of Delhi) and Associated Lok Nayak Hospital, New Delhi, 110002 India.
Seema KapoorDepartment of Paediatrics, Paediatrics Research and Genetic Lab, Maulana Azad Medical College (University of Delhi) and Associated Lok Nayak Hospital, New Delhi, 110002 India.
Maulana Azad Medical College · INUniversity of Delhi · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tyrosinemia type 1 (TYR1) is a devastating aminoacidopathy, leading to mortality without medical intervention. Although, detection and quantification of tyrosine in dried blood spot (DBS) is possible, but being a non-specific marker for TYR1 and its frequent association with transient neonatal tyrosinemia limits its applicability. Despite, Succinylacetone (SUAC) being a pathognomonic marker for TYR1, but not often detectable by routine newborn screening (NBS). We envisaged to determine SUAC in DBS by an in-house flow injection analysis method on a liquid chromatography/tandem mass spectrometry (LC-MS/MS). Succinylacetone was eluted from the residual 3.2 mm DBS of primary NBS by an extraction solution containing acetonitrile-water-formic acid mixture containing stable-isotope labelled internal standard (IS) for SUAC and hydrazine. Detection and quantification was performed by the mass spectrometer using multiple reaction monitoring mode at m/z 155.1 → 109.1 for SUAC and m/z 160.1 → 114.1 for the SUAC IS. The assay was linear over a calibration range of 0.122-117.434 µmol/L. The Intra-day and Inter-day precision and accuracy for the assay was determined at two different levels of SUAC (2.542 µmol/L and 14.641 µmol/L), which showed a coefficient of variation of (6.91% and 12.65%) and (8.57% and 12.27%) respectively. The accuracy also ranged between 101.2 and 103.87%.This method provided the necessary sensitivity, precision, accuracy, recovery and linearity and hence, has the potential to reduce the false positive, false negative results which significantly minimise the cost involved in the screening and follow up of TYR1 patients. SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s12291-020-00944-z) contains supplementary material, which is available to authorized users.

Indexed as

Fumarylacetoacetate hydrolaseInborn errors of metabolismMass spectrometryNewborn screeningTyrosineTyrosinemia type 1

Identifiers

PMID35125692
PMCPMC8799791
OpenAlexW3119641609

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.